Table 1 Clinical trials included in the analysis and fitted parameters for each trial. The study sites are shown in order of increasing transmission intensity, as estimated by the hidden semi-Markov model analysis. Prior EIRs are estimated from the Malaria Atlas Project slide prevalence for each location in the year of the trial [28, 29]
Site and reference | Country, year | PCR correction: molecular markers | N (AL/AS-AQ) | AS-AQ manufacturer (formulation), target AQ dose* | Days of prophylaxis: posterior median (95% CI) | EIR | FOI†| Prevalence of pfmdr1 86Y, % (references) | Prevalence of pfcrt 76T, % (references) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | AL | AS-AQ | Prior mean | Posterior median (95% CI) | Â | Â | Â |
Fougamou [23] | Gabon, 2007–2008 | msp1,msp2,glurp | 68/68 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 11.6 (6.0–16.8) | 13.1 (7.6–18.6) | 0.6 | 2.3 (1.1–4.2) | 0.5 | 79.5 [30] | 97.9 [31] |
Ndola [23] | Zambia, 2007–2009 | msp1,msp2,glurp | 69/64 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 10.8 (6.0–14.8) | 16.1 (9.7–25.0) | 1.2 | 4.8 (2.4–8.4) | 1.0 | No matching survey | 20.8 [32] |
Pweto [33] | Democratic Republic of Congo 2008-2009 | msp1,msp2,glurp | 126/129 | Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg | 11.3 (7.8–14.4) | 17.9 (12.1–25.6) | 50.0 | 9.3 (6.2–13.7) | 2.0 | No matching survey | No matching survey |
Pamol [23] | Nigeria, 2007–2008 | msp1,msp2,glurp | 164/159 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 17.9 (12.3–22.5) | 15.4 (10.3–21.7) | 22.6 | 9.5 (4.7–21.6) | 2.2 | 90.1 [37] | |
Bobo Dioulasso (unpublished‡) | Burkina Faso, 2010–2012 | msp1,msp2 | 373/372 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 12.5 (10.6–14.4) | 16.9 (14.0–19.9) | 21.5 | 17.4 (13.3–23.1) | 5.9 | ||
Gourcy (unpublished‡) | Burkina Faso, 2010–2012 | msp1,msp2 | 112/129 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 8.7 (6.2–10.9) | 17.8 (13.7–22.1) | 22.9 | 23.3 (15.9–33.7) | 6.5 | ||
Kisumu (unpublished‡) | Kenya, 2005 | msp1,msp2 | 179/178 | Sanofi and Hoechst Marion Roussel (Loose NFDC) 30 mg/kg | 18.6 (15.8–21.2) | 14.2 (10.9–17.6) | 6.9 | 26.5 (18.1–39.6) | 5.7 | ||
Nimba [48] | Liberia, 2008–2009 | msp1,msp2,glurp | 127/141 | Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg | 17.9 (15.1–20.6) | 11.6 (8.8–14.3) | 18.3 | 32.4 (26.1–40.0) | 8.0 | 69.4 [49] | 93.5 [49] |
Sikasso [50] | Mali 2005-2007 | msp1,msp2,CA1 | 236/233 | Sanofi-Aventis (Coblistered NFDC. Arsucam) 30 mg/kg | 10.2 (9.0–11.6) | 18.7 (16.1–21.5) | 25.2 | 37.2 (29.5–46.9) | 11.3 | 35.5 [51] | |
Tororo [55] | Uganda, 2009–2010 | msp1,msp2,glurp | 190/190 | Sanofi (AS-AQ Winthrop FDC) 30 mg/kg | 13.3 (11.8–14.6) | 13.4 (11.7–15.1) | 23.3 | 84.2 (72.9–96.9) | 16.9 | ||
Nanoro [23] | Burkina Faso, 2007–2008 | msp1,msp2,glurp | 257/273 | Sanofi-Aventis (FDC Coarsucam) 30 mg/kg | 10.1 (9.2–11.1) | 17.0 (15.0–19.2) | 52.2 | 91.9 (76.2–111.1) | 18.9 | ||
Tororo [60] | Uganda, 2005 | msp1,msp2 | 189/195 | AQ: Parke-David, Pfizer, AS: Sanofi-Aventis (Loose NFDC) 25 mg/kg | 12.4 (11.1–13.8) | 10.2 (8.9–11.6) | 64.6 | 117.1 (98.4–139.8) | 23.3 | ||